FDA Grants IDE Approval for First Synthetic Corneal Endothelial Layer to Treat Chronic Corneal Edema
核心洞察
The FDA has granted Investigational Device Exemption approval to EyeYon Medical for a U.S. clinical study of EndoArt (搜索), the world's first synthetic endothelial layer for treating chronic corneal edema (搜索).
EndoArt (搜索) has been designated as a Breakthrough Device by the FDA and has already been implanted in over 800 patients worldwide with up to seven years of follow-up data.
The clinical investigation will be led by Professor Francis Mah at Scripps Clinic and will include at least 10 leading U.S. cornea surgeons across surgical centers nationwide.
The U.S. Food and Drug Administration has granted Investigational Device Exemption (IDE) approval to EyeYon Medical Ltd. (搜索) for a clinical study of EndoArt (搜索), the world's first synthetic endothelial layer designed to treat chronic corneal edema (搜索). The device, which currently holds FDA Breakthrough Device designation, represents a potentially transformative approach to addressing corneal endothelial diseases (搜索) in a market that exceeds $1 billion globally.
Clinical Study Leadership and Design
The clinical investigation will be led by Professor Francis Mah, MD, Director of Cornea and External Disease at Scripps Clinic Medical Group (搜索). The study will include at least 10 leading U.S. cornea surgeons across surgical centers nationwide, marking a significant expansion of EndoArt (搜索) evaluation into the American market.
"The initiation of this U.S. clinical study marks an exciting moment for our field. EndoArt (搜索) represents a truly novel approach to treating chronic corneal edema (搜索). I'm honored to lead this important investigation and to help evaluate a technology that may reshape the future of endothelial disease management," said Professor Mah.
Addressing Critical Unmet Medical Need
EndoArt (搜索) targets a significant gap in corneal care, where only one cornea is available for every 70 patients in need of transplantation. The synthetic implant is made of sterile biocompatible acrylic hydrophilic material and attaches to the back of the corneal surface through minimally invasive surgery. The device prevents fluid transfer into the cornea, inhibiting the fluid buildup characteristic of corneal edema.
According to EyeYon Medical, the device addresses seven distinct clinical profiles of patients eligible for treatment, including regraft patients experiencing post-graft failure, patients with glaucoma (搜索) drainage implants, those with silicone oil-filled eyes, patients facing tissue shortages and long wait times, non-donor candidates with cultural or religious restrictions, patients with complicated ocular histories, and those with low visual potential outside standard treatment indications.
Global Clinical Experience and Commercial Success
EndoArt (搜索) has demonstrated substantial clinical validation outside the United States, with more than 800 implantations performed worldwide. The device has received CE mark approval and is commercially available in Europe, where it has seen steadily expanding adoption among surgeons. In China, a dedicated clinical trial has progressed successfully, reinforcing the device's safety and effectiveness across diverse patient populations.
The global clinical experience includes up to seven years of follow-up data showing long-term corneal clarity, stability, and sustained therapeutic benefit. This extensive real-world evidence supports EndoArt (搜索)'s position as a transformative treatment option in global corneal care.
Regulatory Pathway and Market Impact
"Securing FDA IDE approval marks a pivotal milestone for EyeYon Medical and for patients suffering from corneal endothelial diseases (搜索)," said Nahum Ferera, CEO of EyeYon Medical. "EndoArt (搜索) has shown rapid adoption in Europe, and this study brings us one step closer to delivering a new hope for patients who are not reasonable candidates for human tissue implantation in the US."
The IDE approval allows the investigational device to be used in clinical studies to collect safety and effectiveness data, permitting lawful shipment for investigation purposes without complying with other Food, Drug, and Cosmetic Act requirements that apply to commercially distributed devices. In the United States, EndoArt (搜索) remains an investigational device limited to investigational use and is not available for sale.